Navigation Links
Fukasaku Small Pupil Irrigating Nucleus Chopper

ProductsFukasaku Small Pupil Irrigating Nucleus Chopper
Company Katena Products, Inc.
Item Fukasaku Small Pupil Irrigating Nucleus Chopper
Features 
Description Small pupil irrigating nucleus chopper, wedge-shaped inferior edge with, blunt tip and front notch, for engaging the iris, 0.6 mm dual sideports, 20 gauge.
Info Katena Products, Inc.
Customer Service: (800) 225-1195
Web site: http://www.katena.com/

Related medicine products :

1. Fukasaku LASIK Spatula
2. Fukasaku Hockey Knife
3. Jameson Muscle Hook - Small
4. Symblepharon Ring - Small
5. Lambert Chalazion Forceps - Small
6. Snellen Entropion Forceps - Small - Right
7. Cervical Retractor Handle - Small
8. Cougar Small Footprint
9. Small Teardrop Dissector
10. Small Spatula Dissector
11. Small Ocelot Stackable Cage System
Other Medicine News:Health News:Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden 2Health News:Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden 3Health News:Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden 4Health News:Garry W. Rogerson Elected Chairman of the Board of Varian, Inc. 2Health News:Smokers Will Stop for Their Pet's Sake 2Health News:Diseased Heart Valve Replaced Through Small Chest Incision 2Health News:Diseased Heart Valve Replaced Through Small Chest Incision 3Health News:Diseased Heart Valve Replaced Through Small Chest Incision 4Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 2Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 3Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 4Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 5Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 6Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 7Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 8Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 9Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 10Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 11Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 12Health News:Shaklee Hits the Road with its Infinite Possibilities Tour in New York, NY 2
Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Within3 Expands into Mobile Applications 2Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 1Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 2Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 3Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 4Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 5Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 1Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 2Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 3Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 5Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 6Industry Professionals Get Schooled in Real World Oncology Issues at NCCN Academy 12512 1Industry Professionals Get Schooled in Real World Oncology Issues at NCCN Academy 12512 2Industry Professionals Get Schooled in Real World Oncology Issues at NCCN Academy 12512 3Industry Professionals Get Schooled in Real World Oncology Issues at NCCN Academy 12512 4